Literature DB >> 10219924

Diagnosis, management, and treatment of Alzheimer disease: a guide for the internist.

S S Richards1, H C Hendrie.   

Abstract

Alzheimer disease (AD) is a diagnosis of inclusion based on patient history, physical examination, neuropsychological testing, and laboratory studies; however, there is no definitive diagnostic test for AD. Early recognition of AD allows time to plan for the future and to treat patients before marked deterioration occurs. Effective treatment requires monitoring of symptoms, functional impairment, and safety, and the use of multiple treatment modalities including pharmacotherapy, behavioral management, psychotherapies, psychosocial treatments, and support and education for families. Pharmacotherapeutic agents available for AD only provide symptomatic relief. The cholinesterase inhibitors, tacrine and donepezil, are effective in improving cognition, delaying nursing home placement, and improving behavioral complications in some patients. Other cholinesterase inhibitors are in development, as are other cholinomimetic agents such as muscarinic and nicotinic receptor agonists. Symptomatic treatments are available for the psychiatric manifestations of AD. Anti-inflammatories, antioxidants, neurotrophic factors, and other agents are promising new treatments for the future.

Entities:  

Mesh:

Year:  1999        PMID: 10219924     DOI: 10.1001/archinte.159.8.789

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  11 in total

1.  Agreement on diagnosis among patients, companions, and professionals after a dementia evaluation.

Authors:  Alexandra K Zaleta; Brian D Carpenter; Emily K Porensky; Chengjie Xiong; John C Morris
Journal:  Alzheimer Dis Assoc Disord       Date:  2012 Jul-Sep       Impact factor: 2.703

2.  National patterns of dementia treatment among elderly ambulatory patients.

Authors:  Mary K Maneno; Euni Lee; Anthony K Wutoh; Ilene H Zuckerman; Patrice Jackson; Fredric A Lombardo; Kenneth R Scott; Zhenyi Xue
Journal:  J Natl Med Assoc       Date:  2006-03       Impact factor: 1.798

3.  The development of a semi-structured home interview (CHIF) to directly assess function in cognitively impaired elderly people in two cultures.

Authors:  H C Hendrie; K A Lane; A Ogunniyi; O Baiyewu; O Gureje; R Evans; V Smith-Gamble; M Pettaway; F W Unverzagt; S Gao; K S Hall
Journal:  Int Psychogeriatr       Date:  2006-04-26       Impact factor: 3.878

4.  Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.

Authors:  Katherine A Lyseng-Williamson; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

5.  Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease.

Authors:  Pamela Sparks Stein; Michelle J Steffen; Charles Smith; Gregory Jicha; Jeffrey L Ebersole; Erin Abner; Dolph Dawson
Journal:  Alzheimers Dement       Date:  2012-05       Impact factor: 21.566

6.  Patient-centered communication during the disclosure of a dementia diagnosis.

Authors:  Alexandra K Zaleta; Brian D Carpenter
Journal:  Am J Alzheimers Dis Other Demen       Date:  2010-06-17       Impact factor: 2.035

Review 7.  Galantamine: a review of its use in Alzheimer's disease.

Authors:  L J Scott; K L Goa
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

8.  Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.

Authors:  Dong-Churl Suh; Stephen Arcona; Simu K Thomas; Christopher Powers; Adrian L Rabinowicz; Hyunchul Shin; Dario Mirski
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 9.  Dementia and its implications for public health.

Authors:  Daniel P Chapman; Sheree Marshall Williams; Tara W Strine; Robert F Anda; Margaret J Moore
Journal:  Prev Chronic Dis       Date:  2006-03-15       Impact factor: 2.830

Review 10.  Economic considerations in the management of Alzheimer's disease.

Authors:  Carolyn W Zhu; Mary Sano
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.